Cargando…
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed dose of 1800 mg. However, the subcutaneous formulation has only recently been approved in Europe, and...
Autores principales: | De Novellis, Danilo, Fontana, Raffaele, Palmieri, Salvatore, Della Pepa, Roberta, Di Perna, Maria, Cetani, Giusy, Esposito, Daniela, Amendola, Angela, Delle Cave, Giuseppe, Serio, Bianca, Morini, Denise, Rizzo, Michela, Mettivier, Laura, Trastulli, Fabio, Rocco, Stefano, Pagano, Anastasia, Barbato, Serafina, Leone, Aldo, La Magna, Martina, Bianco, Rosario, Rascato, Gabriella, Carobene, Angela, Cuffa, Bianca, Iannalfo, Marialuigia, Giudice, Valentina, Svanera, Gino, Annunziata, Mario, Pizzuti, Michele, Frigeri, Ferdinando, Califano, Catello, Ferrara, Felicetto, Pane, Fabrizio, Selleri, Carmine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663178/ https://www.ncbi.nlm.nih.gov/pubmed/37747623 http://dx.doi.org/10.1007/s11523-023-01001-4 |
Ejemplares similares
-
PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
por: De Novellis, D., et al.
Publicado: (2022) -
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022) -
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
por: De Novellis, Danilo, et al.
Publicado: (2022) -
P1544: IMPACT OF SARS-COV 2 INFECTION, IN TREATED NHL-B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE
por: Pezzullo, Luca, et al.
Publicado: (2023) -
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)